home / stock / mbio / mbio news

MBIO News and Press, Mustang Bio Inc. From 12/13/21

Stock Information
Company Name: Mustang Bio Inc.
Stock Symbol: MBIO
Market: NASDAQ
Website: mustangbio.com
Menu
MBIO MBIO Quote MBIO Short MBIO News MBIO Articles MBIO Message Board
Get MBIO Alerts

News, Short Squeeze, Breakout and More Instantly...
MBIO - Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

95% overall response rate, 65% complete response rate and favorable safety profile in patients treated with modified cell manufacturing process Data presented at the 63 rd American Society of Hematology (ASH) Annual Meeting Key opinio...
MBIO - Best Penny Stocks To Buy? 5 To Watch With Potential Catalysts This Week

5 Penny Stocks To Watch With Potential Catalysts It’s the weekend, and we’re nearing the end of the year. But that doesn’t mean the stock market closes anytime soon. December is always an interesting time for traders. Some are looking to cut some heavy bags and harv...

MBIO - Mustang Bio to Host Key Opinion Leader Webinar on MB-106, a Potential Treatment for B-Cell Non Hodgkin Lymphomas and Chronic Lymphocytic Leukemia

Webinar to be held on Thursday, December 16, 2021, at 2:30 p.m. ET WORCESTER, Mass., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs i...

MBIO - Mustang Bio EPS misses by $0.01

Mustang Bio (NASDAQ:MBIO): Q3 GAAP EPS of -$0.19 misses by $0.01. Revenue of $0M Press Release As of September 30, 2021, Mustang’s cash and cash equivalents and restricted cash totaled $121.9 million. For further details see: Mustang Bio EPS misses by $0.01

MBIO - Mustang Bio Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights

WORCESTER, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, sol...

MBIO - Mustang Bio Announces Exclusive Worldwide License Agreement with Leiden University Medical Centre for Clinical-Stage Lentiviral Gene Therapy with Curative Potential for RAG1 Severe Combined Immunodeficiency

Agreement expands Mustang’s pipeline of lentiviral gene therapies for SCID Preclinical development of additional targets to continue at Leiden University WORCESTER, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ:...

MBIO - Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at 63rd American Society of Hematology (ASH) Annual Meeting

WORCESTER, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, sol...
MBIO - Mustang Bio shares rise 4% after $2M NIH grant

Mustang Bio (NASDAQ:MBIO) has been awarded a grant of ~$2M from the National Cancer Institute of the National Institutes of Health (NIH). Shares up more than 4% premarket. The two-year grant will partially fund the company's early-stage trial of MB-106 for patients with relapsed or ...

MBIO - Mustang Bio Awarded NIH Grant For MB-106 CD20-Targeted CAR T Cell Therapy for Treatment of B-cell non-Hodgkin Lymphomas

WORCESTER, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, sol...

MBIO - Mustang Bio to Participate in Chardan's Virtual 5th Annual Genetic Medicines Conference

WORCESTER, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, so...
Previous 10 Next 10